Comparative Pharmacology
Head-to-head clinical analysis: POHERDY versus PSORCON E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POHERDY versus PSORCON E.
POHERDY vs PSORCON E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
POHERDY is a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2), binding to domain IV of the extracellular segment, thereby inhibiting ligand-independent HER2 signaling and mediating antibody-dependent cellular cytotoxicity (ADCC).
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, antipruritic, and vasoconstrictive effects.
POHERDY: No approved drug. No dosing available.
Topical: Apply a thin film to affected skin areas twice daily. No systemic dosing applicable.
None Documented
None Documented
Terminal half-life 12–18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min)
Terminal elimination half-life is approximately 6-8 hours for the parent compound; active metabolites may have half-lives up to 12 hours. Clinically, this supports twice-daily dosing.
Renal: 60% unchanged; fecal/biliary: 30%; 10% metabolized
Primarily hepatic metabolism followed by renal excretion of metabolites; less than 5% excreted unchanged in urine. Biliary/fecal elimination accounts for <2%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid